Transcranial laser therapy in acute stroke treatment: results of neurothera effectiveness and safety trial 3, a phase III clinical end point device trial

Werner Hacke; Peter D Schellinger; Gregory W Albers; Natan M Bornstein; Bjorn L Dahlof; Rachael Fulton; Scott E Kasner; Ashfaq Shuaib; Steven P Richieri; Stephen G Dilly; Justin Zivin; Kennedy R Lees; NEST 3 Committees and Investigators

doi:10.1161/STROKEAHA.114.005795

Back

Transcranial laser therapy in acute stroke treatment: results of neurothera effectiveness and safety trial 3, a phase III clinical end point device trial

Journal article

Open access

Peer reviewed

Transcranial laser therapy in acute stroke treatment: results of neurothera effectiveness and safety trial 3, a phase III clinical end point device trial

Werner Hacke, Peter D Schellinger, Gregory W Albers, Natan M Bornstein, Bjorn L Dahlof, Rachael Fulton, Scott E Kasner, Ashfaq Shuaib, Steven P Richieri, Stephen G Dilly, …

Stroke (1970), Vol.45(11), pp.3187-3193

11/2014

DOI: 10.1161/STROKEAHA.114.005795

PMID: 25293665

Files and links (1)

url

https://doi.org/10.1161/STROKEAHA.114.005795View

Published (Version of record) Open Access

Abstract

On the basis of phase II trials, we considered that transcranial laser therapy could have neuroprotective effects in patients with acute ischemic stroke. We studied transcranial laser therapy in a double-blind, sham-controlled randomized clinical trial intended to enroll 1000 patients with acute ischemic stroke treated ≤24 hours after stroke onset and who did not undergo thrombolytic therapy. The primary efficacy measure was the 90-day functional outcome as assessed by the modified Rankin Scale, with hierarchical Bayesian analysis incorporating relevant previous data. Interim analyses were planned after 300 and 600 patients included. The study was terminated on recommendation by the Data Monitoring Committee after a futility analysis of 566 completed patients found no difference in the primary end point (transcranial laser therapy 140/282 [49.6%] versus sham 140/284 [49.3%] for good functional outcome; modified Rankin Scale, 0-2). The results remained stable after inclusion of all 630 randomized patients (adjusted odds ratio, 1.024; 95% confidence interval, 0.705-1.488). Once the results of the interim futility analysis became available, all study support was immediately withdrawn by the capital firms behind PhotoThera, and the company was dissolved. Proper termination of the trial was difficult but was finally achieved through special efforts by former employees of PhotoThera, the CRO Parexel and members of the steering and the safety committees. We conclude that transcranial laser therapy does not have a measurable neuroprotective effect in patients with acute ischemic stroke when applied within 24 hours after stroke onset. http://www.clinicaltrials.gov. Unique identifier: NCT01120301.

Endpoint Determination - standards

Double-Blind Method

Humans

Middle Aged

Stroke - diagnosis

Endpoint Determination - methods

Male

Treatment Outcome

Patient Safety - standards

Laser Therapy - adverse effects

Female

Laser Therapy - methods

Aged

Stroke - therapy

Details

Title: Subtitle: Transcranial laser therapy in acute stroke treatment: results of neurothera effectiveness and safety trial 3, a phase III clinical end point device trial
Creators: Werner Hacke - From the Department of Neurology, Heidelberg University, Heidelberg, Germany (W.H.); Department of Neurology, Johannes Wesling Klinikum Minden, Minden, Germany (P.D.S.); Department of Neurology, Stanford Stroke Center, Palo Alto, CA (G.W.A.); Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (N.M.B.); Department of Internal Medicine, Sahlgrenski University Hospital Östra, Göteborg University, Göteborg, Sweden (B.L.D.); Institute of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary and Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom (R.F., K.R.L.); Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia (S.E.K.); Division of Neurology, University of Alberta, Edmonton, Alberta, Canada (A.S.); Banyan Biomarkers, San Diego, CA (S.P.R.); Allergen Research Cooperation, San Mateo, CA (S.G.D.); and Department of Neurology, School of Medicine, University of California, San Diego (J.Z.). werner.hacke@med.uni-heidelberg.de
Peter D Schellinger - From the Department of Neurology, Heidelberg University, Heidelberg, Germany (W.H.); Department of Neurology, Johannes Wesling Klinikum Minden, Minden, Germany (P.D.S.); Department of Neurology, Stanford Stroke Center, Palo Alto, CA (G.W.A.); Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (N.M.B.); Department of Internal Medicine, Sahlgrenski University Hospital Östra, Göteborg University, Göteborg, Sweden (B.L.D.); Institute of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary and Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom (R.F., K.R.L.); Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia (S.E.K.); Division of Neurology, University of Alberta, Edmonton, Alberta, Canada (A.S.); Banyan Biomarkers, San Diego, CA (S.P.R.); Allergen Research Cooperation, San Mateo, CA (S.G.D.); and Department of Neurology, School of Medicine, University of California, San Diego (J.Z.)
Gregory W Albers - From the Department of Neurology, Heidelberg University, Heidelberg, Germany (W.H.); Department of Neurology, Johannes Wesling Klinikum Minden, Minden, Germany (P.D.S.); Department of Neurology, Stanford Stroke Center, Palo Alto, CA (G.W.A.); Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (N.M.B.); Department of Internal Medicine, Sahlgrenski University Hospital Östra, Göteborg University, Göteborg, Sweden (B.L.D.); Institute of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary and Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom (R.F., K.R.L.); Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia (S.E.K.); Division of Neurology, University of Alberta, Edmonton, Alberta, Canada (A.S.); Banyan Biomarkers, San Diego, CA (S.P.R.); Allergen Research Cooperation, San Mateo, CA (S.G.D.); and Department of Neurology, School of Medicine, University of California, San Diego (J.Z.)
Natan M Bornstein - From the Department of Neurology, Heidelberg University, Heidelberg, Germany (W.H.); Department of Neurology, Johannes Wesling Klinikum Minden, Minden, Germany (P.D.S.); Department of Neurology, Stanford Stroke Center, Palo Alto, CA (G.W.A.); Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (N.M.B.); Department of Internal Medicine, Sahlgrenski University Hospital Östra, Göteborg University, Göteborg, Sweden (B.L.D.); Institute of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary and Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom (R.F., K.R.L.); Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia (S.E.K.); Division of Neurology, University of Alberta, Edmonton, Alberta, Canada (A.S.); Banyan Biomarkers, San Diego, CA (S.P.R.); Allergen Research Cooperation, San Mateo, CA (S.G.D.); and Department of Neurology, School of Medicine, University of California, San Diego (J.Z.)
Bjorn L Dahlof - From the Department of Neurology, Heidelberg University, Heidelberg, Germany (W.H.); Department of Neurology, Johannes Wesling Klinikum Minden, Minden, Germany (P.D.S.); Department of Neurology, Stanford Stroke Center, Palo Alto, CA (G.W.A.); Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (N.M.B.); Department of Internal Medicine, Sahlgrenski University Hospital Östra, Göteborg University, Göteborg, Sweden (B.L.D.); Institute of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary and Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom (R.F., K.R.L.); Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia (S.E.K.); Division of Neurology, University of Alberta, Edmonton, Alberta, Canada (A.S.); Banyan Biomarkers, San Diego, CA (S.P.R.); Allergen Research Cooperation, San Mateo, CA (S.G.D.); and Department of Neurology, School of Medicine, University of California, San Diego (J.Z.)
Rachael Fulton - From the Department of Neurology, Heidelberg University, Heidelberg, Germany (W.H.); Department of Neurology, Johannes Wesling Klinikum Minden, Minden, Germany (P.D.S.); Department of Neurology, Stanford Stroke Center, Palo Alto, CA (G.W.A.); Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (N.M.B.); Department of Internal Medicine, Sahlgrenski University Hospital Östra, Göteborg University, Göteborg, Sweden (B.L.D.); Institute of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary and Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom (R.F., K.R.L.); Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia (S.E.K.); Division of Neurology, University of Alberta, Edmonton, Alberta, Canada (A.S.); Banyan Biomarkers, San Diego, CA (S.P.R.); Allergen Research Cooperation, San Mateo, CA (S.G.D.); and Department of Neurology, School of Medicine, University of California, San Diego (J.Z.)
Scott E Kasner - From the Department of Neurology, Heidelberg University, Heidelberg, Germany (W.H.); Department of Neurology, Johannes Wesling Klinikum Minden, Minden, Germany (P.D.S.); Department of Neurology, Stanford Stroke Center, Palo Alto, CA (G.W.A.); Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (N.M.B.); Department of Internal Medicine, Sahlgrenski University Hospital Östra, Göteborg University, Göteborg, Sweden (B.L.D.); Institute of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary and Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom (R.F., K.R.L.); Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia (S.E.K.); Division of Neurology, University of Alberta, Edmonton, Alberta, Canada (A.S.); Banyan Biomarkers, San Diego, CA (S.P.R.); Allergen Research Cooperation, San Mateo, CA (S.G.D.); and Department of Neurology, School of Medicine, University of California, San Diego (J.Z.)
Ashfaq Shuaib - From the Department of Neurology, Heidelberg University, Heidelberg, Germany (W.H.); Department of Neurology, Johannes Wesling Klinikum Minden, Minden, Germany (P.D.S.); Department of Neurology, Stanford Stroke Center, Palo Alto, CA (G.W.A.); Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (N.M.B.); Department of Internal Medicine, Sahlgrenski University Hospital Östra, Göteborg University, Göteborg, Sweden (B.L.D.); Institute of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary and Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom (R.F., K.R.L.); Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia (S.E.K.); Division of Neurology, University of Alberta, Edmonton, Alberta, Canada (A.S.); Banyan Biomarkers, San Diego, CA (S.P.R.); Allergen Research Cooperation, San Mateo, CA (S.G.D.); and Department of Neurology, School of Medicine, University of California, San Diego (J.Z.)
Steven P Richieri - From the Department of Neurology, Heidelberg University, Heidelberg, Germany (W.H.); Department of Neurology, Johannes Wesling Klinikum Minden, Minden, Germany (P.D.S.); Department of Neurology, Stanford Stroke Center, Palo Alto, CA (G.W.A.); Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (N.M.B.); Department of Internal Medicine, Sahlgrenski University Hospital Östra, Göteborg University, Göteborg, Sweden (B.L.D.); Institute of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary and Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom (R.F., K.R.L.); Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia (S.E.K.); Division of Neurology, University of Alberta, Edmonton, Alberta, Canada (A.S.); Banyan Biomarkers, San Diego, CA (S.P.R.); Allergen Research Cooperation, San Mateo, CA (S.G.D.); and Department of Neurology, School of Medicine, University of California, San Diego (J.Z.)
Stephen G Dilly - From the Department of Neurology, Heidelberg University, Heidelberg, Germany (W.H.); Department of Neurology, Johannes Wesling Klinikum Minden, Minden, Germany (P.D.S.); Department of Neurology, Stanford Stroke Center, Palo Alto, CA (G.W.A.); Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (N.M.B.); Department of Internal Medicine, Sahlgrenski University Hospital Östra, Göteborg University, Göteborg, Sweden (B.L.D.); Institute of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary and Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom (R.F., K.R.L.); Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia (S.E.K.); Division of Neurology, University of Alberta, Edmonton, Alberta, Canada (A.S.); Banyan Biomarkers, San Diego, CA (S.P.R.); Allergen Research Cooperation, San Mateo, CA (S.G.D.); and Department of Neurology, School of Medicine, University of California, San Diego (J.Z.)
Justin Zivin - From the Department of Neurology, Heidelberg University, Heidelberg, Germany (W.H.); Department of Neurology, Johannes Wesling Klinikum Minden, Minden, Germany (P.D.S.); Department of Neurology, Stanford Stroke Center, Palo Alto, CA (G.W.A.); Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (N.M.B.); Department of Internal Medicine, Sahlgrenski University Hospital Östra, Göteborg University, Göteborg, Sweden (B.L.D.); Institute of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary and Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom (R.F., K.R.L.); Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia (S.E.K.); Division of Neurology, University of Alberta, Edmonton, Alberta, Canada (A.S.); Banyan Biomarkers, San Diego, CA (S.P.R.); Allergen Research Cooperation, San Mateo, CA (S.G.D.); and Department of Neurology, School of Medicine, University of California, San Diego (J.Z.)
Kennedy R Lees - From the Department of Neurology, Heidelberg University, Heidelberg, Germany (W.H.); Department of Neurology, Johannes Wesling Klinikum Minden, Minden, Germany (P.D.S.); Department of Neurology, Stanford Stroke Center, Palo Alto, CA (G.W.A.); Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (N.M.B.); Department of Internal Medicine, Sahlgrenski University Hospital Östra, Göteborg University, Göteborg, Sweden (B.L.D.); Institute of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary and Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom (R.F., K.R.L.); Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia (S.E.K.); Division of Neurology, University of Alberta, Edmonton, Alberta, Canada (A.S.); Banyan Biomarkers, San Diego, CA (S.P.R.); Allergen Research Cooperation, San Mateo, CA (S.G.D.); and Department of Neurology, School of Medicine, University of California, San Diego (J.Z.)
NEST 3 Committees and Investigators
Contributors: Colin P Derdeyn (Contributor) - University of Iowa, Radiology
Resource Type: Journal article
Publication Details: Stroke (1970), Vol.45(11), pp.3187-3193
Publisher: United States
DOI: 10.1161/STROKEAHA.114.005795
PMID: 25293665
ISSN: 0039-2499
eISSN: 1524-4628
Language: English
Date published: 11/2014
Academic Unit: Neurology; Radiology; Iowa Neuroscience Institute; Neurosurgery
Record Identifier: 9984014017302771

Metrics

22 Record Views

86 Times Cited - Web of Science

See more details